A61K 40/22
Immunosuppressive or immunotolerising
A61K40/22 (Immunosuppressive or immunotolerising) appears on 752 US grants and 1,806 published applications in this corpus.
Search patents in A61K- Granted patents
- 752
- Published applications
- 1,806
- Assignees
- 729
- Inventors
- 2,707
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 8 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 10 | 0 |
| 2001 | 8 | 6 |
| 2002 | 14 | 27 |
| 2003 | 8 | 38 |
| 2004 | 10 | 37 |
| 2005 | 4 | 25 |
| 2006 | 8 | 44 |
| 2007 | 4 | 25 |
| 2008 | 10 | 29 |
| 2009 | 12 | 36 |
| 2010 | 19 | 51 |
| 2011 | 18 | 60 |
| 2012 | 12 | 35 |
| 2013 | 19 | 55 |
| 2014 | 30 | 74 |
| 2015 | 26 | 72 |
| 2016 | 36 | 57 |
| 2017 | 32 | 85 |
| 2018 | 53 | 96 |
| 2019 | 27 | 113 |
| 2020 | 48 | 125 |
| 2021 | 48 | 137 |
| 2022 | 47 | 153 |
| 2023 | 55 | 137 |
| 2024 | 59 | 124 |
| 2025 | 70 | 97 |
| 2026 | 41 | 68 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Microparticle-assisted Treg therapy for treatment of tissue injury and fibrosis22 Sep 2026US 12,741,026 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods for hematopoietic stem cell transplants15 Sep 2026US 12,735,678 B2Orca Biosystems, Inc.
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
- Rapamycin resistant cells8 Oct 2026US 2026/0308637 A1Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Methods for stem cell transplantation1 Oct 2026US 2026/0294975 A1The UAB Research Foundation
- Populations of enriched regulatory t cells and methods for producing same1 Oct 2026US 2026/0297523 A1Cellenkos, Inc.
Most cited
By later US patents
- High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")235US 6,040,177 AFred Hutchinson Cancer Research Center · 2000
- CD19-specific chimeric T cell receptor231US 7,446,179 B2City of Hope · 2008
- Method of preparing suppressor T cells with allogeneic mesenchymal stem cells149US 6,281,012 B1Osiris Therapeutics, Inc. · 2001
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens124US 5,994,126 AThe Rockefeller University · 1999
- Mesenchymal stem cells as immunosuppressants110US 6,797,269 B2Osiris Therapeutics, Inc. · 2004